AFP (HR, 1.546; 95% CI, 1.175–2.030; P = 0.002), vascular invasion (HR, 1.655; 95% CI, 1.251–2.190; P < 0.001), tumor size (HR, 3.593; 95% CI, 2.540–5.080; P < 0.001), and TACE therapy combined with H101 or not (HR, 0.668; 95% CI, 0.518–0.860; P = 0.002) were independent factors in decreasing cancer-specific mortality. The gene discussed is AFP; the disease is cancer.